Research Projects & Grants

Federal

  • A phase II multi-center study of rapamycin for treating kidney angiomyolipomas in TSC or LAM patients, Role: Investigator, National Institutes of Health/DHHS, (06/2010 - 06/2011) Status: Completed
  • Focal segmental glomerulosclerosis trial, Role: Investigator, National Institutes of Health/DHHS, (01/2008 - 01/2009) Status: Completed
  • TGF beta and the progression of renal disease, Role: Investigator, National Institutes of Health/DHHS, (05/2007 - 05/2008) Status: Completed

For Profit Organization

  • An open-label, single-arm, multicenter study to ascertain the optimal starting dose of Mircera® given subcutaneously for the maintenance treatment of Anemia in pediatric patients with chronic kidney disease on dialysis or not yet on dialysis, Role: Investigator, Hoffmann-La Roche Inc., (04/2021 - 04/2022) Status: Completed
  • A retrospective observational study to describe changes in biochemical markers and occurrence of safety events following treatment with cinacalcet HCI in pediatric subjects with chronic kidney disease and secondary hyperparathyroidism receiving dialysis, Role: Investigator, Amgen, Inc., (11/2010 - 11/2011) Status: Completed
  • NCGS 85-036, substudy 11 Genentech National cooperative growth study (NCGS) post marketing surveillance program for nutropin depot® [somatropin (rDNA origin) for injection], nutropin AQ® [somatropin (rDNA origin) injection], nutropin® [somatropin (rDNA origin) for injection], and protropin® [somatrem for injection], Role: Investigator, Genentech, Inc., (04/2009 - 04/2010) Status: Completed
  • Luitpold Pharmaceuticals, Inc. – IVEN03017 – Comparison of the safety and efficacy of three Venofer® iron maintenance regimens in pediatric chronic kidney disease patients, Role: Investigator, Luitpold Pharmaceuticals, Inc., (11/2007 - 11/2008) Status: Completed
  • PEDS I (Pediatric eplerenone development study I): A randomized, double-blind, placebo withdrawal, parallel group, dose-response study to evaluate the efficacy and safety of eplerenone in the treatment of hypertension in children, Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (08/2005 - 08/2006) Status: Completed
  • Use of Rituximab in pediatric solid organ recipients with post transplant lymphoproliferative disorders: an open label phase II multicenter non-randomized study, Role: Investigator, IDEC Pharmaceuticals Corporation, (01/2004 - 01/2005) Status: Completed
  • Treatment of drug-resistant adult and pediatric primary focal segmental glomerulosclerosis using the Liposorber LA-15 System, Role: Investigator, Kaneka Medical America LLC, (03/2025 - 03/2026) Status: Approved

Internal

  • North American Pediatric Renal Trials Collaborative Studies (NAPRTCS), Role: Investigator, LLU Dept. of Pediatrics, (06/2024 - 06/2025) Status: Approved
  • Rituximab use in nephrotic syndrome, Role: Investigator, LLU Dept. of Pediatrics, (04/2016) Status: Completed
  • A prospective study of citrate based dialysate in pediatric patients receiving intermittent hemodialysis, Role: Investigator, LLU Dept. of Pediatrics, (04/2015 - 04/2016) Status: Completed
  • The role of PTH in renal osteodystrophy, Role: Investigator, LLU Dept. of Pediatrics, (10/2012 - 10/2013) Status: Completed
  • Impact of a "challenge" intervention on weight control in pediatric patients with kidney disease and diabetes: a retrospective analysis of patient records, Role: PI, LLU Dept. of Pediatrics, (11/2009 - 11/2010) Status: Completed